66 Recruiting Studies Using Acalabrutinib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Acalabrutinib
Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease
📍 Moffitt Cancer Center — Tampa, Florida
Recurrent Moderate-Severe Chronic Graft Versus Host Disease
View Study & Checklist ➔A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Liver Lymphoma
View Study & Checklist ➔Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
📍 Alaska Oncology and Hematology, LLC — Anchorage, Alaska
Lymphoma, Mantle-Cell
View Study & Checklist ➔A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
📍 Research Site — Tucson, Arizona
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
📍 Research Site — Chandler, Arizona
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
📍 Research Site — Phoenix, Arizona
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
📍 Washington University School of Medicine — St Louis, Missouri
Primary Central Nervous System Lymphoma
View Study & Checklist ➔Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
📍 Research Site — Los Angeles, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
📍 Massachusetts General Hospital — Boston, Massachusetts
Refractory Aggressive B-cell Lymphomas
View Study & Checklist ➔Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma
📍 BC Cancer Agency — Vancouver, British Columbia
Mantle Cell Lymphoma
View Study & Checklist ➔ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy
📍 Massachusetts General Hospital — Boston, Massachusetts
IgM MGUS
View Study & Checklist ➔A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL
📍 Research Site — Louisville, Kentucky
Mantle Cell Lymphoma (MCL)
View Study & Checklist ➔Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
📍 Weill Cornell Medicine — New York, New York
Mantle Cell Lymphoma
View Study & Checklist ➔A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
Lymphoma
View Study & Checklist ➔Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
Mantle Cell Lymphoma
View Study & Checklist ➔Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
Ann Arbor Stage III Grade 1 Follicular Lymphoma
View Study & Checklist ➔Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
📍 City of Hope Medical Center — Duarte, California
Autoimmune Hemolytic Anemia
View Study & Checklist ➔Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
B-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
📍 Research Site — Tucson, Arizona
Non Hodgkin Lymphoma
View Study & Checklist ➔Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
📍 M D Anderson Cancer Center — Houston, Texas
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
📍 Research Site — Goodyear, Arizona
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
📍 City of Hope Medical Center — Duarte, California
Mantle Cell Lymphoma
View Study & Checklist ➔A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
📍 Research Site — Hackensack, New Jersey
Mantle Cell Lymphoma (MCL)
View Study & Checklist ➔Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
📍 Stamford Hospital/Bennett Cancer Center — Stamford, Connecticut
Chronic Lymphocytic Leukemia (CLL)
View Study & Checklist ➔An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
📍 Research Site — Santa Barbara, California
Waldenström Macroglobulinemia (WM)
View Study & Checklist ➔ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
📍 Research Site — Boston, Massachusetts
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
📍 Research Site — Columbus, Ohio
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
Mantle Cell Lymphoma
View Study & Checklist ➔A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
📍 Moffit Cancer Center — Tampa, Florida
Central Nervous System Lymphoma
View Study & Checklist ➔Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
Blastoid Variant Mantle Cell Lymphoma
View Study & Checklist ➔Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
📍 Dana Farber Cancer Institute — Boston, Massachusetts
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
📍 Tom Baker Cancer Centre — Calgary, Alberta
Waldenstrom Macroglobulinemia
View Study & Checklist ➔A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
📍 Memorial Sloan Kettering Basking Ridge (All protocol activities) — Basking Ridge, New Jersey
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
📍 Research Site — Tucson, Arizona
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
View Study & Checklist ➔A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
📍 Research Site — Tucson, Arizona
Lymphoma, Mantle Cell
View Study & Checklist ➔Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
📍 Mount Sinai Hospital — New York, New York
Mantle Cell Lymphoma
View Study & Checklist ➔Acalabrutinib in CNSL
📍 Brigham and Women's Hospital — Boston, Massachusetts
Central Nervous System Lymphoma
View Study & Checklist ➔Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
📍 City of Hope Medical Center — Duarte, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Mosunetuzumab for CLL MRD Clearance
📍 Brigham & Women's Hospital — Boston, Massachusetts
Leukemia
View Study & Checklist ➔A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
📍 Research Site — Boston, Massachusetts
Chronic Lymphocytic Leukaemia
View Study & Checklist ➔Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
Recurrent Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
📍 Arizona Oncology - Tucson - Rudasill /ID# 267552 — Tucson, Arizona
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Recurrent Chronic Lymphocytic Leukemia
View Study & Checklist ➔Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
📍 University of Cincinnati — Cincinnati, Ohio
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
📍 Goshen Center for Cancer Care — Goshen, Indiana
Diffuse Large B Cell Lymphoma
View Study & Checklist ➔Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
View Study & Checklist ➔Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
📍 City of Hope Medical Center — Duarte, California
Mantle Cell Lymphoma
View Study & Checklist ➔A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
📍 USA Mitchell Cancer Institute ( Site 0014) — Mobile, Alabama
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
📍 Research Site — Boston, Massachusetts
Chronic Lymphocytic Leukemia (CLL)
View Study & Checklist ➔Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
📍 City of Hope National Medical Center — Duarte, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
📍 Mayo Clinic in Arizona — Scottsdale, Arizona
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Grade 1 Follicular Lymphoma
View Study & Checklist ➔Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
📍 Research Site — Berkeley, California
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
📍 Research Site — Charlotte, North Carolina
Chronic Lymphocytic Leukaemia
View Study & Checklist ➔A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
📍 Emory University Hospital — Atlanta, Georgia
Indolent B-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
📍 MD Anderson Cancer Center — Houston, Texas
Phase 2 Study
View Study & Checklist ➔Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
📍 OHSU Knight Cancer Institute — Portland, Oregon
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
📍 Stanford Cancer Institute Palo Alto — Palo Alto, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Non-Hodgkin's Lymphoma
View Study & Checklist ➔Avo In R/R And Previously Untreated MCL
📍 University of Chicago Medical Center — Chicago, Illinois
Mantle Cell Lymphoma
View Study & Checklist ➔Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Recurrent Mantle Cell Lymphoma
View Study & Checklist ➔